About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘oncology retractions’ Category

Cancer researcher has correction upgraded to retraction

with 11 comments

mol endo coverRakesh Kumar, a researcher with six recent corrections and one retraction, has had one of those corrections upgraded to a retraction.

Here’s the unhelpful notice, from Molecular Endocrinology: Read the rest of this entry »

About these ads

“Our jaws hit the floor!!” Researchers say authors doctored images for rebuttal letter

with 7 comments

eurourologyTry to follow along on this one. We think it’s worth it.

The authors of a letter replying to a comment in a urology journal have retracted their response because it contained inappropriate figures. At least, that’s the official story.

The original paper, “Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy,” came from a group at Weill Medical College of Cornell University led by Ashutosh Tewari. Published in July 2012 in European Urology, it purported to find that: Read the rest of this entry »

MD Anderson postdoc faked results of Novartis anti-cancer compound study

with 35 comments

jun fu

Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).

Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:

Read the rest of this entry »

Written by Ivan Oransky

August 1, 2014 at 8:00 am

UT-Southwestern cancer research group notches ninth retraction

with one comment

lung cancerA research team at the University of Texas-Southwestern that has retracted eight papers for image manipulation has retracted another, this one in Lung Cancer.

Here’s the notice for “Aberrant methylation of Reprimo in lung cancer,” published by Adi Gazdar’s group: Read the rest of this entry »

Paper about widely touted but unapproved “cure” for cancer, autism retracted

with 11 comments

int j cancerA paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.

Here’s the notice from the International Journal of Cancer about a 2007 paper purporting to show that the substance, GcMAF, is useful against breast cancer: Read the rest of this entry »

“Lack of experience and understanding” forces duplication retractions of liver cancer paper

with one comment

dovelogoA group of researchers in China has lost their paper on liver cancer after the first author admitted to duplication, also known, inelegantly, as self-plagiarism.

The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.

According to the abstract: Read the rest of this entry »

PLOS ONE retracts breast cancer genetics paper after claim of misappropriated data

with 5 comments

plosonePLOS ONE has retracted a 2012 article by a group of breast cancer researchers after another scientist — a leading U.S. oncologist — objected that the data came from his lab.

The paper, “GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer,” came from a team composed of researchers at the Morehouse School of Medicine, Xavier University of Louisiana and the University of Miami School of Medicine. It purported to find that: Read the rest of this entry »

Written by Adam Marcus

July 17, 2014 at 9:30 am

Follow

Get every new post delivered to your Inbox.

Join 34,509 other followers